Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.

Current oncology (Toronto, Ont.)·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.

Current oncology (Toronto, Ont.)·2026
Same author

High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis.

Current oncology (Toronto, Ont.)·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Jan 3, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Extramedullary multiple myeloma.

Manisha Bhutani1, David M Foureau2, Shebli Atrash1

  • 1Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

Leukemia
|November 29, 2019
PubMed
Summary

Extramedullary multiple myeloma (EMM) is a rare, aggressive form of multiple myeloma where cancer cells grow outside the bone marrow. Understanding EMM's biology is key to developing better treatments for this high-risk condition.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.6K

Related Experiment Videos

Last Updated: Jan 3, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.6K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma.
  • EMM is characterized by plasma cell growth independent of the bone marrow microenvironment.
  • This leads to increased proliferation, apoptosis evasion, and treatment resistance, resulting in poor patient outcomes.

Purpose of the Study:

  • To discuss the evolutionary biology of EMM.
  • To emphasize the need for a standardized definition of EMM.
  • To review current and emerging therapeutic strategies for EMM.

Main Methods:

  • Literature review and synthesis of existing research on EMM.
  • Analysis of molecular mechanisms driving plasma cell homing outside the bone marrow.
  • Discussion of prognostic factors and treatment outcomes in EMM.

Main Results:

  • EMM represents a high-risk state in multiple myeloma.
  • Understanding the molecular basis of EMM is crucial for targeted therapies.
  • Current treatment strategies show limited efficacy, highlighting the need for novel approaches.

Conclusions:

  • EMM requires a uniform definition for accurate diagnosis and research.
  • Targeting the microenvironment and specific signaling pathways is essential for managing EMM.
  • Further research into EMM's evolutionary biology will guide the development of more effective treatments.